echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Positive data from the STP705 phase IIa study for the treatment of squamous cell skin cancer

    Positive data from the STP705 phase IIa study for the treatment of squamous cell skin cancer

    • Last Update: 2020-12-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Squamous cells are the main cells of the skin structure.
    the United States, more than 1 million people are diagnosed with squamous cell carcinoma each year and 2,500 die from the disease.
    squamous cell carcinoma (the second most common skin cancer, after substrate cell carcinoma) generally occurs in the area of daylight exposure, people with more sunlight have a higher risk of squamous cell skin cancer, white people are susceptible to the disease.
    , a biopharmaceutical company focused on RNAi drugs, announced today that its leading candidate drug, STP705, has achieved positive results in its Phase IIa clinical study of squamous cell skin cancer.
    the trial consisted of five dose incremental trial groups, ranging from 10 to 120 μg, with a total of 25 patients in each group.
    participants received STP705 injections once a week for up to six weeks.
    the main endpoint of the trial is to assess the histological clearance rate of tumor cells within the lesions.
    showed that 76% (19/25) of all patients achieved complete histological removal.
    90% lesions histological removal was achieved in the two optimal dosage ranges.
    no significant adverse events associated with treatment were reported in the study, nor were there serious adverse events.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.